Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01178 (oxytocin)
 15,767 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Terlipressin (Remestyp) or N-a-triglycyl-(8-lysme) vasopressin after parenteral application and slow enzymatic cleavage releases synthetic analog of vasopressin-8-lysine-vasopressin. It is potent myometrial stimulator in pregnant and non-pregnant uterus and at the same time decreases myometrial and endometrial blood flow. Remestyp has synergistic effect with oxytocin and/or methergin. Our experience shows good effect of Remestyp in the complex treatment of cases with hypotonic uterus, placenta praevia or adherence during and after abdominal or vaginal birth. Injection of Remestyp around the fibroids during cesarean section significantly decrease the blood lost and make the myomectomy safer. We observe decrease of oozing at the incision of the skin and stopping initial subfascial hematoma.
 ...
PMID:[The use of the vasoconstrictor hemostatic Remestyp in surgical obstetrics]. 1073 87

Activation of arginine-vasopressin is one of the hormonal responses to face vasodilation-related hypotension. Released from the post-pituitary gland, vasopressin induces vasoconstriction through the activation of V1a receptors located on vascular smooth muscle cells. Due to its non-selective receptor affinity arginine-vasopressin also activates V2 (located on renal tubular cells of collecting ducts) and V1b (located in the anterior pituitary and in the pancreas) receptors, thereby potentially promoting undesired side effects such as anti-diuresis, procoagulant properties due to release of the von Willebrand's factor and platelet activation. Finally, it also cross-activates oxytocin receptors. During septic shock, vasopressin plasma levels were reported to be lower than expected, and a hypersensitivity to its vasopressor effect is reported in such situation. Terlipressin and selepressin are synthetic vasopressin analogues with a higher affinity for the V1 receptor, and, hence, potentially less side effects. In this narrative review, we present the current knowledge of the rationale, benefits and risks of vasopressin use in the setting of septic shock and vasoplegic shock following cardiac surgery. Clearly, vasopressin administration allows reducing norepinephrine requirements, but so far, no improvement of survival was reported and side effects are frequent, particularly ischaemic events. Finally, we will discuss the current indications for vasopressin and its agonists in the setting of septic shock, and the remaining unresolved questions.
 ...
PMID:Vasopressin and its analogues in shock states: a review. 3197 May 67